Sanuwave Health Posts Record Results Amid CMS Shock

Sanuwave Health Inc. ((SNWV)) has held its Q4 earnings call. Read on for the main highlights of the call.

Sanuwave Health’s latest earnings call painted a picture of robust growth colliding with a harsh reimbursement reset across its wound-care market. Management highlighted record revenue, expanding margins, and improving liquidity, yet repeatedly warned that CMS cuts and audits are weighing on some customers and near‑term growth, leaving investors balancing strong execution against elevated external risk.

Record Quarterly Revenue

Q4 revenue reached a company record of $13.4 million, up 30% from $10.3 million a year ago and squarely in line with guidance of $13 million to $14 million. Management stressed that this top‑line performance was achieved despite mounting pressure from reimbursement changes that have unsettled many wound‑care providers.

Strong Full-Year Growth

For fiscal 2025, Sanuwave generated $44.1 million in revenue, a 35% jump over 2024 that underscores strong demand for its UltraMIST technology. Adjusted EBITDA nearly doubled to $13.6 million from $7.2 million, signaling improving operating leverage even as the company absorbed higher expenses and industry turbulence.

Material Increase in System Sales

UltraMIST system sales were a standout, with 624 units sold in 2025 versus 374 the prior year, a 67% surge that deepens the installed base. Q4 alone set a new placement record at 255 systems, beating the prior quarterly high by 100 units and positioning Sanuwave for future consumables growth.

Improved Profitability and EBITDA

Fourth‑quarter adjusted EBITDA rose to $4.8 million from $3.7 million, while reported EBITDA reached $8.7 million as profitability continued to trend higher. Net income swung sharply to a $7.7 million profit in Q4 from a $13.3 million loss a year earlier, driven largely by favorable noncash fair‑value changes in derivative liabilities.

Gross Margin Strength and Consumables Demand

Full‑year gross margin expanded to roughly 77%, reflecting better pricing on consumables and lower system costs. Consumables volume climbed 24% and system sales 67%, reinforcing Sanuwave’s high‑margin razor‑and‑blade model and offering some cushion against future reimbursement and cost pressures.

Stronger Liquidity and Current Assets

The balance sheet improved, with current assets rising to $24.6 million from $18.4 million a year earlier and cash and equivalents reaching $12.0 million at year‑end. Management framed the stronger liquidity as strategic firepower to weather industry disruption and support continued investment in growth initiatives.

Channel Expansion and New Reseller Strategy

Sanuwave is leaning into a pivot toward stocking resellers and wholesale distribution, which began in Q3 and accelerated in Q4. About 32% of Q4 revenue flowed through outside resellers and distributors, up from 26% in Q3, and management expects these partnerships to expand UltraMIST’s reach while delivering attractive margin contribution.

Refinancing and Reduced Volatility

The refinancing of senior debt with JPMorgan late in Q3 helped lower interest expense and simplified the capital structure. With most outstanding warrants now exercised, exchanged, or expired, management expects future results to show fewer noncash swings tied to derivative liabilities, making earnings quality easier for investors to assess.

CMS Reimbursement Shock and Industry Audits

The call repeatedly returned to the impact of CMS cuts on skin substitutes, which slashed reimbursement to around $127 per cm2, a roughly 90% to 95% price reduction. Coupled with a bill‑only‑what‑you‑apply policy and intense audits, this has squeezed practitioner economics, reduced patient volumes, and contributed to customer stress across the wound‑care landscape.

Discontinued Systems and Customer Churn

Industry disruption showed up in Sanuwave’s field base, with 168 UltraMIST systems removed from active counts in Q4 as discontinued or inactive. Many of these units were tied to clinics that shut down or stopped ordering, and management characterized this level of churn as unusually elevated but linked to the extraordinary reimbursement shock.

Sales Tax Restatement and Incremental Charges

A sales‑tax review identified previously unrecognized liabilities, leading to restated figures in the Form 10‑K and higher general and administrative expense. The company booked roughly $1.6 million of extra G&A and $0.1 million of interest in 2024, plus similar G&A and about $0.3 million of interest in 2025, with some additional remediation costs expected in early 2026.

Inventory Write-Offs and Product Sunsetting

Sanuwave also used Q4 to clean up its portfolio, sunsetting the dermaPACE and Profile product lines and recording a $486,000 PACE inventory write‑off. That decision trimmed Q4 gross margin by about 320 basis points, and management noted that excluding the write‑off, gross margin would have been a robust 78.3%, reinforcing the core business’s profitability.

Higher Operating Expenses and One-Time Items

Operating expenses climbed to $8.0 million in Q4, roughly $2.0 million higher than the prior year, as the company absorbed several one‑time and structural cost increases. Drivers included changes in stock‑based compensation and accrual reversals of about $1 million net, higher payroll of $358,000, elevated R&D non‑personnel spending of $483,000, and sales‑tax‑related charges.

Near-Term Headwinds and Modest Q1 Outlook

Management acknowledged that near‑term growth is constrained, with Q1 revenue guidance of $9.6 million to $10.3 million implying just 3% to 10% year‑over‑year expansion. They tied the slower start to ongoing CMS‑related disruption and the timing of channel shifts, and issued a wide 16% to 25% full‑year growth range to reflect the uncertain pace of recovery.

Manufacturing and Supply Timing Risks

The company is working to qualify a new applicator mold that should boost applicator margins by several hundred basis points once fully ramped. However, delays in that qualification have pushed out the expected manufacturing scale‑up, and management refused to commit to a firm timetable, flagging ongoing supply‑chain timing risk for investors.

Forward-Looking Guidance and Expectations

Looking ahead, Sanuwave guided Q1 revenue to $9.6 million to $10.3 million, with management cautioning that the quarter will remain muted by CMS‑driven turbulence. For the full year, they outlined a preliminary revenue range that implies 16% to 25% growth and suggested that roughly half of incremental revenue should flow through to EBITDA, with expectations for stronger momentum in the back half as reseller channels and inventory levels normalize.

Sanuwave’s earnings call showcased a company executing well financially while navigating one of the toughest reimbursement resets its niche has seen. Record revenue, expanding margins, and a larger UltraMIST footprint offer long‑term promise, but investors will need to watch customer churn, reimbursement trends, and execution on channel and manufacturing initiatives as key drivers of whether the growth story stays on track.